Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 14/20 | 0.59 |
| ▸ | TACR3 | P29371 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA4 | P22748 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TACR2 | P21452 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12809374 | 0.92 | TACR1 (0.65) | TACR1TACR3CA1CA2CA4 | |
| SCHEMBL14422707 | 0.91 | TACR1 (0.68) | TACR1TACR3CA1CA2CA4 | |
| SCHEMBL13756720 | 0.88 | TACR1 (0.61) | TACR1TACR3CA1CA2CA4 | |
| SCHEMBL4986742 | 0.87 | TACR1 (0.68) | TACR1TACR3CA1CA2CA4 | |
| SCHEMBL4993782 | 0.87 | TACR1 (0.68) | TACR1TACR3CA1CA2CA4 | |
| SCHEMBL1400878 | 0.87 | TACR1 (0.68) | TACR1TACR3CA1CA2CA4 | |
| SCHEMBL1400874 | 0.87 | TACR1 (0.68) | TACR1TACR3CA1CA2CA4 | |
| SCHEMBL14217214 | 0.87 | TACR1 (0.61) | TACR1TACR3USP2 | |
| SCHEMBL13980765 | 0.86 | TACR1 (0.67) | TACR1TACR3USP2CYP3A4 | |
| SCHEMBL14217020 | 0.86 | TACR1 (0.58) | TACR1TACR3USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1737838-B1 | SUBSTITUTED 4-ALKYL- AND 4-ALKANOYL-PIPERIDINE DERIVATIVES AND THEIR USE AS NEUROKININ ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2008-05-21 | — | — | EP | disclosed |
| US-20070213346-A1 | Substituted 4-Alkyl-And 4-Alkanoyl-Piperidine Derivatives And Their Use As Neurokinin Antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-09-13 | — | — | US | disclosed |
| US-20070213346-A1 | Substituted 4-Alkyl-And 4-Alkanoyl-Piperidine Derivatives And Their Use As Neurokinin Antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213346-A1 | Substituted 4-Alkyl-And 4-Alkanoyl-Piperidine Derivatives And Their Use As Neurokinin Antagonists | NPSR1, VIP, OPRK1 | TACR1 36/4885TACR3 214/4885CA1 3189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.